Skip to content

Study · Animal study (in vivo) · mouse · 2021

1 result

Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice.

Novoselova EG, Glushkova OV, Lunin SM, Khrenov MO, Parfenyuk SB, Novoselova TV, Sharapov MG, Gordeeva AE, Novoselov VI, Fesenko EE

International journal of immunopathology and pharmacology1 Jan 2021Cited by 9 (Europe PMC)

PMID33779346 (opens in a new tab)PMCIDPMC8010817 (opens in a new tab)DOI10.1177/20587384211005645 (opens in a new tab)PepBankPUB-33779346
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with streptozotocin-induced diabetes, thymulin reduced physiological impairments at various levels.

    In plain wordsIn mice with diabetes, thymulin reduced physiological impairments.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreasePhysiological impairments
    Study

    mousen: not reported in source

    Streptozotocin-induced type 1 diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both thymulin and PRDX6 reduced the physiological impairments in diabetic mice at various levels.
    2 context sentences
    Summary · context
    The present work was aimed at studying the efficiency of thymulin and PRDX6 in a type 1 diabetes mellitus model induced by streptozotocin in mice.
    Summary · context
    Effects of prolonged treatment with PRDX6 or thymic peptide thymulin on diabetes development were evaluated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.